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Abstract: (350) 25 
Objective: To evaluate the value of fetal scalp blood sampling (FBS) as an adjunct test to 26 
cardiotocography, to predict adverse neonatal outcomes. 27 
Study design: A multicentre service evaluation observational study in forty-four maternity units 28 
in the UK. We collected data retrospectively on pregnant women with singleton pregnancy who 29 
received FBS in labour using a standardised data collection tool. The primary outcome was 30 
prediction of neonatal acidaemia diagnosed as umbilical cord arterial pH<7.05, the secondary 31 
outcomes were the prediction of Apgar scores<7 at 1st and 5th minutes and admission to the 32 
neonatal intensive care unit (NICU). We evaluated the correlation between the last FBS blood 33 
gas before birth and the umbilical cord blood and adjusted for time intervals. We constructed 2x2 34 
tables to calculate the sensitivity, specificity, positive (PPV) and negative predictive value (NPV) 35 
and generated receiver operating curves to report on the Area Under the Curve (AUC). 36 
Results: In total, 1422 samples were included in the analysis; pH values showed no correlation 37 
(r=0.001, p=0.9) in samples obtained within an hour (n=314), or within half an hour from birth 38 
(n=115) (r=-0.003, p=0.9). A suboptimal FBS pH value (<7.25) had a poor sensitivity (22%) and 39 
PPV (4.9%) to predict neonatal acidaemia with high specificity (87.3%) and NPV (97.4%). 40 
Similar performance was noted to predict Apgar scores <7 at 1st (sensitivity 14.5%, specificity 41 
87.5%, PPV 23.4%, NPV 79.6%) and 5th minute (sensitivity 20.3%, specificity 87.4%, PPV 42 
7.6%, NPV 95.6%), and admission to NICU (sensitivity 20.3%, specificity 87.5%, PPV 13.3%, 43 
NPV 92.1%). The AUC for FBS pH to predict neonatal acidaemia was 0.59 (95%CI 0.59-0.68, 44 
p=0.3) with similar performance to predict Apgar scores<7 at 1st minute (AUC 0.55, 95%CI 45 
0.51-0.59, p=0.004), 5th minute (AUC 0.55, 95%CI 0.48-0.62, p=0.13), and admission to NICU 46 
(AUC 0.58, 95%CI 0.52-0.64, p=0.002)  47 
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Forty-one neonates had acidaemia (2.8%, 41/1422) at birth. There was no significant correlation 48 
in pH values between the FBS and the umbilical cord blood in this subgroup adjusted for 49 
sampling time intervals (r= 0.03, p=0.83). 50 
Conclusions: As an adjunct tool to cardiotocography, FBS offered limited value to predict 51 
neonatal acidaemia, low Apgar Scores and admission to NICU.    52 
Funding: None 53 
Keywords: Fetal scalp – Blood sampling – Intrapartum – Accuracy – Acidaemia – Asphyxia  54 
55 
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Introduction: 56 
Fetal surveillance in labour is an essential practice in modern obstetric to monitor fetal wellbeing 57 
and reduce the risk of adverse neonatal outcomes. Cardiotocography (CTG) remains the primary 58 
tool to monitor the fetal heart rate and screen for intrapartum hypoxia, however, due to its low 59 
specificity, several adjunct diagnostic tools have been proposed to increase its accuracy.(1) Fetal 60 
scalp blood sampling (FBS) is proposed as an objective test to assess the fetal metabolic status in 61 
labour, measuring capillary pH and base excess values, thus prompting further interventions 62 
when fetal acidaemia is suspected. Still, its effectiveness as an adjunct tool to CTG to improve 63 
perinatal outcomes remains uncertain.(2)  64 
 65 
In practice, many factors can affect the accuracy of FBS to predict fetal compromise such as 66 
sample contamination, failure to obtain samples timely and underlying fetal complications like 67 
anaemia and infection.(3) Such limitations call to question the value of using FBS as a gold 68 
standard to evaluate the fetal metabolic status (4) especially within the diagnostic thresholds set 69 
in current national guidelines.(2) We conducted a multi-centre observational service evaluation 70 
study to assess the value of using FBS in labour to predict neonatal acidaemia and associated 71 
adverse neonatal outcomes  72 
 73 
Methods: 74 
Study design 75 
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The study was conducted by members of The UK trainee Audit and Research Collaborative in 76 
Obstetrics and Gynaecology (UKARCOG.org). The corresponding author is the study guarantor 77 
and assumes responsibility for the completeness and accuracy of the data and analyses, and for 78 
the fidelity of the study to the registered protocol. 79 
 80 
The study protocol was conceived by the UKARCOG core group and approved by all 81 
collaborators. We registered the protocol prospectively with the clinical governance department 82 
at each of the participating maternity units. A copy of the protocol is publicly available on the 83 
internet (www.UKARCOG.org). Our project was exempt from ethical approval as a service 84 
evaluation study collecting data routinely recorded in the National Health Service (NHS).  85 
 86 
Participants 87 
We collected data retrospectively on pregnant women with a singleton pregnancy who 88 
underwent FBS in labour and had umbilical cord blood gases recorded at birth. We identified 89 
participants by screening the logs of blood gas analysers at participating units for paired FBS and 90 
umbilical cord blood samples and then linked data to the women’s electronic or paper-based 91 
clinical notes. Samples with no paired pH values on both the FBS and the umbilical cord blood 92 
gas were excluded. Samples with no paired arterial and venous umbilical cord blood gas were 93 
also excluded from the analysis.  94 
 95 
Outcome measures 96 
The primary outcome was the accuracy to predict neonatal acidaemia defined as an arterial 97 
umbilical cord pH value <7.05.(2) The secondary outcomes were the accuracy to predict Apgar 98 
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scores<7 at the1st minute and the 5th minute, and admission to the neonatal intensive care unit 99 
(NICU). We defined a FBS pH value as normal if it was >7.25, suboptimal if it was 7.25-7.20 100 
and abnormal if it was <7.20. We defined a FBS lactate value as normal if it was <4.2, 101 
suboptimal if it was 4.2-4.8 and abnormal if it was >4.8.(2)   102 
 103 
We collected data on the: gestation age at delivery, gravidity, parity, duration of 1st and 2nd 104 
stages of labour, incidence of maternal pyrexia (>38.0 Cₒ) in labour, incidence of meconium-105 
stained liquor in labour, birth weight, date and time of each FBS sample, cervical dilation at each 106 
FBS sample, pH value, base excess value and lactate value on each FBS sample, date and time of 107 
birth, birth outcome, mode of delivery, cord blood gas pH, base excess and lactate values, Apgar 108 
scores at 1st and 5th minute of life, and admission to the NICU. Low birth weight was defined as 109 
<2500g.  110 
 111 
Data collection 112 
We collected data using a standardised paper-based data collection tool (Appendix 1). All 113 
collaborators were debriefed on the use of the tool and confirmed its face validity. Collected 114 
forms were coded, anonymised and entered into a standardised Excel-based database locally at 115 
each participating unit. Anonymised data were merged centrally for the purpose of the analysis 116 
as per the registered protocol.    117 
 118 
Statistical analysis 119 
We used the results of the last FBS before birth and the umbilical cord blood gas test values 120 
to construct 2x2 tables and calculate the sensitivity, specificity, positive predictive value 121 
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(PPV) and negative predictive value (NPV) for each of the following test thresholds to 122 
predict the primary and secondary outcomes: suboptimal pH, abnormal pH, suboptimal 123 
lactate and abnormal lactate. We generated receiver operating characteristic curves for 124 
these test thresholds and reported on the Area Under the Curve (AUC) with 95% 125 
confidence intervals (CI) to predict adverse neonatal outcomes with lower test values 126 
indicating a more positive test. We used Pearson and partial correlation tests to evaluate 127 
the correlation between the pH values on the FBS and the umbilical cord blood samples 128 
adjusted for sampling time intervals . We performed a multivariate logistic regression 129 
modelling to determine factors affecting the accuracy of FBS and reported using relative 130 
risk (RR) and 95%CI on the association between each FBS pH threshold and relevant 131 
maternal and neonatal adverse outcomes. All statistical analyses were performed in SPSS 132 
v20 (IBM Corp. Armonk, NY). 133 
 134 
Results 135 
General findings 136 
We collected data on 1670 women who received a FBS in labour, sample dates ranged between 137 
January 2016 and May 2018. We excluded 248 records due to incomplete data, and included 138 
1422 in the analysis. FBS was performed twice in 373 women, three times in 59, and four times 139 
in 17 women.    140 
The median gestation age was 40+3 (range 34+2 - 42+1), and the median birth weight was 3405 141 
(range 1940 - 5050). Labour was induced in two-thirds of women (59.6%, 844/1422) and 20% 142 
had a normal vaginal delivery (20.4%, 297/1421). Almost half of the included women were 143 
delivered via emergency caesarean section (43.1%, 613/1421) and 36% had a vaginal 144 
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instrumental delivery (35.6%, 507/1421). The incidence of maternal pyrexia in labour was 10.7% 145 
(153/1422) and meconium stained liquor was diagnosed in 18.9% (269/1422). Only 10.4% of 146 
neonates had a low birth weight <2500g (10.4%, 148/1422). (Table 1) 147 
 148 
A total of 296 fetuses had an Apgar scores <7 at 1st minute (296/1422, 20.8%) and 69 had a 149 
scores <7 at the 5th minute (69/1422, 4.8%). Only 8% needed admission to NICU (118/1422, 150 
8.2%). A quarter of fetuses had a suboptimal pH (<7.25) on the last FBS test before birth 151 
(12.9%, 184/1422) and 77 had an abnormal pH (<7.20) (5.4%, 77/1422). Lactate was only 152 
available in 187 FBS tests and was suboptimal (>4.2) in 31 fetuses (16.5%, 31/187) and 153 
abnormal in 23 (12.2%, 23/187). 154 
Overall there was poor correlation between FBS blood markers and those on the umbilical cord 155 
(pH r= 0.22, p=0.001; BE r= 0.36 p=0.001; Lactate r=0.23, p=0.002). We evaluated the 156 
correlation between the pH values of the FBS and the umbilical cord arterial blood gas in 157 
samples performed within an hour from birth and adjusted for sampling time intervals. There 158 
was no significant correlation (r=0.001, p=0.9) in pH values in samples obtained within an hour 159 
(n=314) from birth, or in those within half an hour from birth (n=115) (r=-0.003, p=0.9). 160 
A suboptimal FBS pH value (<7.25) had a poor sensitivity (22%) and PPV (4.9%) to predict 161 
neonatal acidaemia with high specificity (87.3%) and NPV (97.4%). Similar performance was 162 
noted to predict Apgar scores <7 at 1st (sensitivity 14.5%, specificity 87.5%, PPV 23.4%, NPV 163 
79.6%) and 5th minute (sensitivity 20.3%, specificity 87.4%, PPV 7.6%, NPV 95.6%), and 164 
admission to NICU (sensitivity 20.3%, specificity 87.5%, PPV 13.3%, NPV 92.1%) (Table 2). 165 
Similarly, an abnormal FBS pH (<7.20) had low sensitivity (7.3%) and PPV (3.9%) and high 166 
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specificity (94.6%) and NPV (97.2%) for neonatal acidaemia with similar performance to predict 167 
the remaining adverse neonatal outcomes (Table 2).  168 
 169 
Our ROC analysis revealed a modest performance for FBS pH to predict neonatal acidaemia 170 
with an AUC of 0.59 (95%CI 0.59-0.68, p=0.3) (Figure 1) and similar performance for 171 
predicting Apgar scores <7 at 1st minute (AUC 0.55, 95%CI 0.51-0.59, p=0.004), 5th minute 172 
(AUC 0.55, 95%CI 0.48-0.62, p=0.13), and admission to NICU (AUC 0.58, 95%CI 0.52-0.64, 173 
p=0.002). (Table 2) (Appendix 3)  174 
 175 
Neonatal acidaemia was diagnosed in 41 neonates (2.8%, 41/1422). Over half of those neonates 176 
had an Apgar score <7 at the 1st minute (63.4%, 26/41), 6 had a score <7 at the 5th minute 177 
(14.6%, 6/41), and 7 required admission to NICU (17%, 7/41) (Table 1). Twenty were delivered 178 
via an emergency caesarean section (20/41, 48.7%) and 13 via an instrumental vaginal delivery 179 
(13/41,31.7%). FBS was conducted in the second stage of labour in 10 of these foetuses (10/41, 180 
24.3%). There was no significant correlation in pH values between the FBS and the umbilical 181 
cord samples in this subgroup adjusted for sampling time intervals (range 15-462 minutes) (r= 182 
0.03, p=0.83), similar findings were found for BE (r=0.29, p=0.08). Paired Lactate samples were 183 
available in only five cases in this subgroup.  184 
 185 
Due to the small sample size of paired pH and lactate (n=187), we were unable to accurately 186 
evaluate the performance of suboptimal and abnormal FBS lactate to predict the primary and 187 
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secondary outcomes. Overall lactate showed a similar performance to pH with high specificity 188 
and NPV and low sensitivity and PPV for all adverse neonatal outcomes (Appendix 2).  189 
 190 
Associated factors 191 
Women with a suboptimal FBS pH had a RR of 1.62 (95%CI 1.42-1.83) to receive an emergency 192 
caesarean section. A similar risk was reported for those with an abnormal FBS pH (RR 1.82, 193 
95%CI 1.58-2.10). Repeating the FBS three or more times in labour was associated with a RR of 194 
1.22 for receiving an emergency caesarean section (95%CI 0.95-1.57). There was no significant 195 
association between the FBS pH value and the diagnosis of maternal pyrexia (BE -.246, p=0.37),  196 
the diagnosis of meconium stained liquor in labour (BE -.119, p=0.55) or the mode of delivery 197 
(vaginal vs emergency caesarean section BE 0.298, p=0.058). There was a negative association 198 
with low birth weight (BE -.461, p=0.045). 199 
 200 
Discussion 201 
Summary of findings 202 
Our study suggests an overall limited value for using FBS as an adjunct test to CTG to predict 203 
adverse outcomes in fetuses at risk of intrapartum asphyxia. FBS pH demonstrated high 204 
specificity and negative predictive value to predict neonatal acidaemia, thus, it is a good test to 205 
rule out uncompromised fetuses with an abnormal CTG test, but not to rule in those at risk.  206 
Women who had a suboptimal or abnormal FBS pH value had a higher risk of receiving an 207 
emergency caesarean section, however, we were not able to record the indication for delivery in 208 
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all cases. Interestingly, only a small number of babies delivered via an emergency caesarean 209 
section were found to have marked neonatal acidaemia (20/659, 1.4%). This comes in line with 210 
evidence suggesting that using FBS did not reduce the rate of emergency caesarean section as 211 
hoped.(5) FBS pH values did not correlate with those on the umbilical cord within an hour of 212 
delivery or in those neonates with acidaemia at birth, suggesting a limited value of using FBS to 213 
aid decision making in labour with a modest AUC for predicting all adverse neonatal outcomes 214 
ranging from 0.55 to 0.59.  215 
 216 
Strength and limitations 217 
We collected data from 44 maternity units which provide a pragmatic national perspective on the 218 
current use of FBS in the NHS. We registered our protocol prospectively at each participating 219 
maternity unit and used a standardised data collection tool to reduce performance bias. We 220 
obtained a large and diverse sample, though interestingly many women were induced (60%) and 221 
only a fifth had a normal vaginal delivery (20%). This could support an association between 222 
using FBS and increased risk in labour leading to higher rate of interventions.  223 
Our findings are not without limitations, we collected data retrospectively across multiple sites to 224 
obtain a large sample and improve the study power, , however, we could not obtain consecutive 225 
cases across all sites The practice of FBS is standardised across the NHS and reported outcomes 226 
are collected routinely in standardised maternity records as per established national guidelines. 227 
We, therefore, do not perceive significant variation in data collection. We did not record the 228 
indication for performing the FBS and presumed it to follow an abnormal intrapartum CTG. 229 
Variations in CTG interpretations, prompting FBS testing, are likely and our findings should be 230 
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interpreted pragmatically. Our study design is subject to the treatment paradox, interventions to 231 
prompt early delivery and neonatal resuscitation at birth are likely to mend the metabolic status 232 
of compromised neonates, thus improving their umbilical cord pH values. Performing in utero 233 
resuscitation such as change in maternal position and use of tocolytics could also change the fetal 234 
metabolic status from time of FBS to time of birth. We planned to adjust correlation testing for 235 
sampling time intervals between the last FBS and time of birth. However, our data suffered from 236 
high loss of times recorded and we could only adjust in samples within an hour of birth.  237 
We aimed to collect data from all maternity units in the UK, but several units withdraw due to 238 
low numbers of FBS tests performed per year. We collected a limited number of samples where 239 
FBS lactate was recorded which reduced our ability to accurately evaluate its predictive value.   240 
 241 
Implication for clinical practice 242 
The primary aim of using FBS is to improve the detection of intrapartum hypoxia and reduce 243 
unnecessary interventions when a CTG is judged to be abnormal. Due to its limited specificity, 244 
using CTG as the sole fetal surveillance tool could increase the rate of unnecessary caesarean 245 
sections and the associated adverse neonatal and maternal outcomes.(5) Our findings support the 246 
ability of a normal FBS pH to reassure health professionals and mothers on the safety of a fetus 247 
with an abnormal CTG. However, a suboptimal or abnormal pH using current thresholds seems 248 
of limited value to guide further action. This echoes the findings of similar studies confirming 249 
the limited value of FBS pH to aid decision making in intrapartum care.(6)  Adopting a more 250 
comprehensive evaluation of the fetal metabolic status using BE and Lactate in addition to pH 251 
could offer better guidance to clinicians.(7)  252 
13 
 
The current national guideline in the UK recommends performing a FBS when a CTG is judged 253 
to be ‘pathological’.(2) However, with many diagnostic criteria used to classify and interpret 254 
CTG in labour, the poor inter/intra-rater reliability could lead to excessive use of FBS. Some 255 
CTG features are considered more abnormal than others (2,8,9), evaluating the correlation 256 
between certain CTG features and the findings on the FBS capillary pH could offer better 257 
guidance on if and when FBS is warranted. Developing a deeper understanding of the fetal 258 
pathophysiology and the fetal response to intrapartum hypoxic stress may obviate the need for 259 
FBS.(10) 260 
 261 
Current guidance supports the validity of FBS predictive value for an hour in the first stage of 262 
labour and half an hour in the second stage.(2) However, there is limited evidence on the 263 
longitudinal changes in pH values in labour. This was evident in our sample with no apparent 264 
correlation in pH values within an hour from birth. Khuehle et al presented better correlation in 265 
pH value within an hour from birth (6), though their findings did not adjust for sampling time 266 
intervals. Clearly, the depreciation rate in the fetal pH during intrapartum hypoxic stress depends 267 
on the individual reserve of the fetus, the rapidity and the intensity of intrapartum hypoxia. 268 
Therefore, from a pathophysiological point of view, having ‘arbitrary’ cut offs (60 minutes or 30 269 
minutes) to obtain new samples appears illogical. A threshold for the maximum number of 270 
repeated FBS samples in labour remains unknown. Recent evidence suggested that repetitive 271 
fetal blood sampling may double the caesarean section rate (11) which is consistent in our 272 
findings with a RR of 1.62 . 273 
The use of capillary lactate seems to offer an easier and more versatile test with reduced failure 274 
rate to obtain a sample.(12) Our sample was not sufficient to evaluate its performance as a 275 
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predictive test and more research is needed to evaluate its role in modern obstetrics. Several 276 
studies reported better correlation in Lactate values between FBS and cord samples (13,14), still 277 
no evidence in improving neonatal or maternal outcomes was noted in two randomised trials. 278 
(15) 279 
 280 
Future research 281 
To date, many adjunct tests to CTG have been proposed to aid the diagnosis of intrapartum 282 
hypoxia.(12) While several meta-analyses evaluated their efficacy,(12) there is limited evidence 283 
on their accuracy as predictive tools in everyday practice. 284 
The current technology employed to obtain fetal capillary blood is largely undeveloped since its 285 
introduction in 1960.(10) Improving the sample acquisition process might increase the FBS 286 
accuracy and effectiveness by reducing sample collection failure and contamination.(4) The use 287 
of FBS pH should be critically reviewed in the light of our findings, and recent evidence 288 
advocating the value of fetal scalp stimulation to provide better information with on fetal 289 
wellbeing.(16) Fetal surveillance is a complex intervention with many confounding factors such 290 
as the availability of trained staff and the complexity of associated maternal co-morbidity in 291 
labour. Evaluating the efficacy of fetal surveillance tools in randomised trials offers a snapshot 292 
evaluation of a standardised practice during the lifetime of the trial.(17) Thus, larger 293 
effectiveness and longitudinal multicentre follow-ups studies are needed to draw more accurate 294 
conclusions and contrast the benefit of using these tools to improve short and long-term neonatal 295 
and maternal outcomes.    296 
 297 
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Conclusion: As an adjunct tool to cardiotocography, FBS offered limited value to predict 298 
neonatal acidaemia, low Apgar Scores and admission to NICU.    299 
 300 
Acknowledgement:  301 
- The authors appreciate with great gratitude the input of Mr Edwin Chandraharan - 302 
Consultant Obstetrician and Gynaecologist at St. George’s NHS Trust- who critically 303 
reviewed and improved our manuscript.  304 
- The trainees of the UKARCOG network appreciate the help and guidance received from 305 
consultants on the RCOG academic board and participating NHS maternity units to 306 
accomplish this study.  307 
Funding: None 308 
Disclosure of interest: All authors have nothing to declare 309 
Contribution to authorship: 310 
Bassel H.Al Wattar conceived the idea, wrote the first protocol and manuscript, analysed the data 311 
and acted as the study chief investigator. William Parry smith, Nicola Tempest, Mathew Prior, 312 
Jennifer Tamblyn, Jonathan Frost and Emma Long revised the protocol and acted as the study 313 
management committee. All remaining co-authors actively collected data, oversaw the study 314 
conduct and contributed critically to the final manuscript.   315 
16 
 
References: 316 
1.  Devoe LD. Future perspectives in intrapartum fetal surveillance. Best Pract Res Clin 317 
Obstet Gynaecol. 2016;30:98–106.  318 
2.  The National Institute for Health and Care Excellence. Intrapartum care for healthy 319 
women and babies. 2014; Available from: https://www.nice.org.uk/guidance/cg190 320 
3.  Jacobson L, Rooth G. Interpretative aspects on the acid‐ base composition and its 321 
variation in fetal scalp blood and maternal blood during labour. BJOG An Int J Obstet 322 
Gynaecol. 1971;78(11):971–80.  323 
4.  Mahendru AA, Lees CC. Is intrapartum fetal blood sampling a gold standard diagnostic 324 
tool for fetal distress? Eur J Obstet Gynecol Reprod Biol. 2011;156(2):137–9.  325 
5.  Alfirevic Z, Devane D, Gyte GM. Continuous cardiotocography (CTG) as a form of 326 
electronic fetal monitoring (EFM) for fetal assessment during labour. Cochrane Database 327 
Syst Rev. 2006;3(3):81.  328 
6.  Kuehnle E, Herms S, Kohls F, Kundu S, Hillemanns P, Staboulidou I. Correlation of fetal 329 
scalp blood sampling pH with neonatal outcome umbilical artery pH value. Arch Gynecol 330 
Obstet. 2016;294(4):763–70.  331 
7.  Heinis AMF, Spaanderman ME, Gunnewiek JMTK, Lotgering FK. Scalp blood lactate for 332 
intra‐ partum assessment of fetal metabolic acidosis. Acta Obstet Gynecol Scand. 333 
2011;90(10):1107–14.  334 
8.  Ayres‐ de‐ Campos D, Spong CY, Chandraharan E. FIGO consensus guidelines on 335 
intrapartum fetal monitoring: Cardiotocography. Int J Gynecol Obstet. 2015;131(1):13–336 
17 
 
24.  337 
9.  Kouskouti C, Jonas H, Regner K, Ruisinger P, Knabl J, Kainer F. Validation of a new 338 
algorithm for the short-term variation of the fetal heart rate: an antepartum prospective 339 
study. J Perinat Med. 2018;46(6):599–604.  340 
10.  Chandraharan E. Fetal scalp blood sampling during labour: is it a useful diagnostic test or 341 
a historical test that no longer has a place in modern clinical obstetrics? BJOG An Int J 342 
Obstet Gynaecol. 2014;121(9):1056–62.  343 
11.  Holzmann M, Wretler S, Cnattingius S, Nordström L. Neonatal outcome and delivery 344 
mode in labors with repetitive fetal scalp blood sampling. Eur J Obstet Gynecol Reprod 345 
Biol. 2015;184:97–102.  346 
12.  Wiberg-Itzel E, Lipponer C, Norman M, Herbst A, Prebensen D, Hansson A, et al. 347 
Determination of pH or lactate in fetal scalp blood in management of intrapartum fetal 348 
distress: randomised controlled multicentre trial. Bmj. 2008;336(7656):1284–7.  349 
13.  Kruger K, Hallberg B, Blennow M, Kublickas M, Westgren M. Predictive value of fetal 350 
scalp blood lactate concentration and pH as markers of neurologic disability. Am J Obstet 351 
Gynecol. 1999;181(5):1072–8.  352 
14.  Kastendieck E, Paulick R, Martius J. Lactate in fetal tissue during hypoxia; correlation to 353 
lactate, pH and base deficit in the fetal blood. Eur J Obstet Gynecol Reprod Biol. 354 
1988;29(1):61–71.  355 
15.  East CE, Leader LR, Sheehan P, Henshall NE, Colditz PB, Lau R. Intrapartum fetal scalp 356 
lactate sampling for fetal assessment in the presence of a non‐ reassuring fetal heart rate 357 
18 
 
trace. Cochrane Database Syst Rev. 2015;(5).  358 
16.  Tahir Mahmood U, O’Gorman C, Marchocki Z, O’Brien Y, Murphy DJ. Fetal scalp 359 
stimulation (FSS) versus fetal blood sampling (FBS) for women with abnormal fetal heart 360 
rate monitoring in labor: a prospective cohort study. J Matern Neonatal Med. 361 
2018;31(13):1742–7.  362 
17.  Ayres-de-Campos D. Introduction: why is intrapartum foetal monitoring necessary–363 
impact on outcomes and interventions. Best Pract Res Clin Obstet Gynaecol. 2016;30:3–8.  364 
 365 
 366 
